Abstract
Following oral administration to animals and humans, drugs are absorbed, transported via portal circulation to the liver, and metabolized primarily via this organ. In general, drugs are predominantly metabolized by the oxidation of parent drug, which is typically mediated by cytochrome P450 (CYP450) enzymes. To a lesser degree, flavin monooxidation (FMO), as well as the reduction or cleavage of the parent drug via enzymatic (i.e., esterase and amidase) or nonenzymatic hydrolysis, forms other phase I metabolites. Subsequent conjugation (phase II reaction) of the phase I metabolites can produce glucuronide, sulfate, glutathione, glycine, and acetate conjugated metabolites. In many cases, hepatic in vitro metabolism studies can yield valuable preliminary information on the in vivo metabolism of a compound of interest by the liver. Experimental in vitro hepatic systems using hepatocytes, 9000g supernatant (S9), and microsomal fractions are presently used to characterize the in vitro metabolism of xenobiotics. Following the incubation of drugs with either of the systems above, solvent or solid-phase extraction, radio-TLC (14C/3H-labeled drugs), high-performance liquid chromatography (HPLC) (radiolabeled or unlabeled), liquid chromatography/mass spectrometry (LC/MS), nuclear magnetic resonance (NMR), and derivatization (phenolic, alcoholic, carboxylic, and/or amino metabolites) techniques are commonly used to analyze and evaluate the metabolic stability of drugs (percentage of parent remaining), as well as to quantify, characterize, and identify drug metabolites and their derivatives. In this chapter, valuable in vitro methods using animal and human hepatic S9, as well as human liver microsomal fractions, and unique techniques for estimating and understanding metabolic stability, as well as profiling and identifying metabolites, will be discussed for use in drug discovery and drug evaluation phases of a drug’s development.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
La Du, B. N., Mandel, H. G., and Way, E. L., eds. (1972) Fundamentals of Drug Metabolism and Drug Disposition. Williams & Wilkins, Baltimore.
Testa, B. and Jenner, P., eds. (1976) Drug Metabolism: Chemical and Biochemical Aspects. Marcel Dekker, New York.
Jenner, P. and Testa, B., eds. (1980–1981) Concepts in Drug Metabolism Parts A and B. Marcel Dekker, New York.
Parkinson, A. (1996) Biotransformation of xenobiotics, in Casarett & Doull’s Toxicology, (Klaassen, C. D., ed.), pp. 113–186.
Ortiz de Montellano, P. R., ed. (1995) Cytochrome P450: Structure, Mechanism and Biochemistry. Plenum, New York.
Omura, T. (1999) Forty years of cytochrome P450. Biochem. Biophys. Res. Commun. 266, 690–698.
Rendic, S. and Di Carlo, F. J. (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413–580.
Cashman, J. R. (2000) Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr. Drug Metab. 1, 181–191.
Mulder, G. J., ed. (1990) Conjugation Reactions in Drug Metabolism. Taylor & Francis, London.
Radominska-Pandya, A., Czernik, P. J., Little, J. M., Battaglia, and Mackenzie, E. (1999) Structural and functional studies of UDP-glucuronosyltransferase. Drug Metab. Rev. 31, 817–899.
King, C. D., Rios, G. R., Green, M. D., and Tephly, T. R. (2000) UDP-glucuronosyltransferases. Curr. Drug Metab. 1, 143–161.
Banoglu, E. (2000) Current status of the cytosolic sulfotransferases in the metabolic activation of promutagens and procarcinogens. Curr. Drug Metab. 1, 1–30.
Li, A. P. (2001) Screening for human ADME/Tox drug properties in drug discovery. DDT 6, 357–366.
White, R. E. (2000) High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu. Rev. Pharmacol. Toxicol. 40, 133–157.
Uetrecht, J. P. (2000) Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr. Drug Metab. 1, 107–132.
Wu, W. N. and McKown, L. A. (2000) Recent advances in biotransformation of cns and cardiovascular agents. Curr. Drug Metab. 1, 255–270.
Wu, W. N., McKown, L. A., Yorgey, K. A., and Pritchard, J. F. (1999) In vitro metabolic products of RWJ-34130, an antiarrhythmic agent, in rat liver preparations. J. Pharm. Biomed. Anal. 20, 687–695.
McKown, L. A., Wu, W. N., and O’Neill, P. J. (1994) Characterization and identification of the metabolites of fenoctimine using in vitro drug metabolizing systems. J. Pharm. Biomed. Anal. 6, 771–775.
Wu, W. N., McKown, L. A., and O’Neill, P. J. (1995) In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat. J. Pharm. Sci. 84, 185–189.
Wu, W. N., McKown, L. A., Moyer, M. D., Johannsen, T. B., and Takacs, A. R. (1999) In vitro metabolism of mifepristone (RU-486) in rat, monkey and human hepatic S9 fractions: identification of three new mifepristone metabolites. Xenobiotica 31, 1089–1100.
Wu, W. N., McKown, L. A., Gauthier, A. D., Jones, W. J., and Raffa, R. B. (2001) Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog. Xenobiotica 31, 423–441.
Wu, W. N., McKown, L. A., and Liao, S. (2002) Metabolism of the analgesic drug, ULTRAM® (tramadol hydrochloride) in humans: api-ms and ms/ms characterization of metabolites. Xenobiotica 32, 411–425.
Yan, Z., Caldwell, G. W., Wu, W. N., McKown, L. A., Rafferty, B., Jones, W. J., et al. (2002) In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica 32, 949–962.
Wu, W. N., McKown, L. A., and Reitz, A. B. (2001) In vitro metabolism of the anxiolytic agent, RWJ-52763 in human hepatic S9 fraction [abstract #243]. The 6th International ISSX Meeting. Drug Metab. Rev. 33, 122.
Wu, W. N., McKown, L. A., and Reitz, A. B. (2003) In vitro metabolism of the new anxiolytic agent, RWJ-52763 in human hepatic S9 fraction—api-ms/ms identification of metabolites. J. Pharm. Biomed. Anal. 31, 95–102.
Wu, W. N., McKown, L. A., and Rybczynski, P. J. (2000) In vitro metabolism of the endocrine agent, RWJ-68025, in rat and human hepatic S9 fraction [abstract #230]. The 10th North American ISSX Meeting. Drug Metab. Rev. 32, 251.
Wu, W. N., McKown, L. A., Rybczynski, P. J., and Demarest, K. (2003) Hepatic biotransformation of the new calcium-mimetic agent, RWJ-68025, in the rat and in man—api-ms/ms identification of metabolites. J. Pharm. Pharmacol. 55, 631–637.
Tang, C., Hochman, J. H., Ma, B., Subramanian, R., and Vyas, K. P. (2003) Acyl glucuronidation and glucosidation of a new and selective endothelin ETA receptor antagonist in human liver microsomes. Drug Metab. Dispos. 31, 37–45.
McKown, L. A., Wu, W. N., and Pritchard, J. F. (1992) In vitro metabolism of McN-4130 (RWJ-34130) in the rat [abstract]. Presented at the AAPS Eastern Regional Meeting.
Wu, W. N., Masucci, J. A., Caldwell, G. W., and Carson, J. R. (1998) Excretion and metabolism of the antihypertensive agent, RWJ-26240 (McN-5691) in dogs. Drug Metab. Dispos. 26, 115–125.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Wu, WN., McKown, L.A. (2004). In Vitro Drug Metabolite Profiling Using Hepatic S9 and Human Liver Microsomes. In: Yan, Z., Caldwell, G.W. (eds) Optimization in Drug Discovery. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1385/1-59259-800-5:163
Download citation
DOI: https://doi.org/10.1385/1-59259-800-5:163
Publisher Name: Humana Press
Print ISBN: 978-1-58829-332-9
Online ISBN: 978-1-59259-800-7
eBook Packages: Springer Protocols